The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice
sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of
sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared
with current best practice, reduces the length of ICU stay.